Hubei Biocause Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net income was CNY 274.05 million compared to CNY 470.71 million a year ago. Basic earnings per share from continuing operations was CNY 0.06 compared to CNY 0.1 a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.31 CNY | +0.87% | -2.94% | -18.66% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.66% | 1.58B | |
+14.51% | 79.29B | |
+9.69% | 51.58B | |
+3.49% | 48.51B | |
+20.18% | 46.18B | |
+13.73% | 42.35B | |
+27.66% | 40.27B | |
+6.85% | 31.18B | |
-1.87% | 29.34B | |
+21.31% | 23.4B |
- Stock Market
- Equities
- 000627 Stock
- News Hubei Biocause Pharmaceutical Co., Ltd.
- Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022